Accueil   Diary - News   All news Focus on Alizé Pharma

Focus on Alizé Pharma

Alizé Pharma, a company member of Lyonbiopole,announces that it has raised €1.8 million (USD $1.94 million) in a first financing round. The funding round was supported by a syndicate of investors that included Sofimac Partners via their FCPI Emergence Innovation 1 seed capital fund, Octalfa, Sham Innovation Santé, Rhône-Alpes Création, Crédit Agricole Création, CEMA and TAB Consulting.

Alizé Pharma III will use the funds to conduct a pharmacology and lead optimization program on a family of peptides with anabolic effects on the bone. The I-HBD1 program will be performed in collaboration with Alizé Pharma III’s US partner New Paradigm Therapeutics Inc., a spin-off from the University of North Carolina at Chapel Hill founded by Dr. David Clemmons. The aim of the program is to select a drug candidate that will enter development for the treatment of osteoporosis and other diseases with impaired bone metabolism in 2016.

 

Read the press release

 

 Alizé Pharma is a group of companies specialized in the development of innovative biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases and rare diseases. The management is a team of drug development experts. The board of directors has a breadth of international experience. Its business strategy is to advance programs based on medical innovation to the clinical stage and establish partnerships with pharmaceutical companies to secure both short- and long-term revenue streams. Since its creation in 2007 the group has raised €15.1 million from private and institutional investors. It has advanced two programs to the clinical phase and has also signed its first industrial partnership. Alizé Pharma SAS is working on a peptide derived from unacylated ghrelin (AZP- 531). This program is in Phase II clinical development for the treatment of Prader-Willi syndrome and in Phase Ib for type 2 diabetes. Alizé Pharma II SAS is focusing on the development of ASPAREC®, a new pegylated recombinant L-asparaginase for the treatment of acute lymphoblastic leukemia (ALL). It is partnered with Jazz Pharmaceuticals (Nasdaq: JAZZ) and is currently in Phase II/III clinical development. Founded in 2014, Alizé Pharma III SAS has acquired exclusive worldwide rights to develop and commercialize a family of new peptides with bone anabolic properties.
www.alz-pharma.com

 

 

 

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree